|
CA2672524A1
|
|
Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
|
|
AU2006203260A1
|
|
Treatment of Central Nervous System Disorders by Use of PDGF or VEGF
|
|
WO2005081619A2
|
|
Compounds and methods for increasing neurogenesis
|
|
CA2544125A1
|
|
Use of ephrins and related molecules to regulate cellular proliferation
|
|
WO2005025553A2
|
|
Treatment of disorders of nervous systemsystem with fty720
|
|
US6969702B2
|
|
Compounds and methods for increasing neurogenesis
|
|
EP1583541A2
|
|
Compounds and methods for increasing neurogenesis
|
|
AU2003267749A1
|
|
Method for retrospective birth dating of biomolecules, cells, tissues, organs and organisms
|
|
WO2004018655A2
|
|
Method for culturing stem cells
|
|
AU2003233119A8
|
|
Modulation of neural stem cells with s1p or lpa receptor agonists
|
|
EP1507551A2
|
|
The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells
|
|
AU2002339128A1
|
|
Use of reelin, gas6, and protein s in the treatment of neural disorders
|
|
CA2466333A1
|
|
Method of proliferation in neurogenic regions
|
|
US7981863B2
|
|
Treatment of Parkinson's disease with PDGF
|
|
AU3879402A
|
|
Methods and compositions involved in groucho-mediated differentiation
|
|
GB0013260D0
|
|
Method
|
|
AU4945999A
|
|
Ependymal neural stem cells and method for their isolation
|
|
US6541247B1
|
|
Method of isolating ependymal neural stem cells
|
